Abstract
Background
McArdle disease, a common metabolic myopathy with autosomal recessive inheritance, is caused by a frequent R50X mutation and many rare mutations in the myophosphorylase gene.
Objectives
To identify spectrum and frequencies of myophosphorylase gene mutations in a large cohort of patients with McArdle disease, to discuss diagnostic implications, and to analyse genotype–phenotype relationship.
Methods
Molecular genetic analysis of 56 index patients with muscle biopsy-proven myophosphorylase deficiency from Germany (n = 35), UK (n = 13), and several other countries (n = 8) was performed using direct sequencing.
Results
Allele frequency of the R50X mutation was 58%, and 71% of the patients carried this mutation at least on one allele. We detected 26 other less common mutations, 13 of which are novel: G157V, R161C, Q337R, E384K, S450L, G486D, R570W, K575E, IVS6-2A>T, IVS10+1G>A, R650X, c.1354insC, c.1155_1156delGG. There was no genotype-phenotype correlation with respect to age of onset and severity. R270X was the most frequent mutation among the less common mutations reaching an allele frequency of 5% followed by R94W and G686R representing a frequency of 4% each.
Conclusions
The study further extends the genetic heterogeneity of myophosphorylase gene mutations showing no mutational hotspot and no genotype–phenotype correlation. Most novel missense mutations were located in secondary structures or active sites of the enzyme. Some of the less common mutations are recurrent with different frequencies within Europe. Ethnic origin and frequency of less common mutations must be considered to establish efficient strategies in molecular genetic testing. Performing molecular testing can avoid muscle biopsy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartram C, Edwards RH, Clague J, Beynon RJ (1993) McArdle’s disease: A nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 2:1291–1293
Deschauer M, Opalka JR, Lindner A, Zierz S (2001) A novel nonsense mutation (R269X) in the myophosphorylase gene in a patient with McArdle disease. Mol Genet Metab 74:489–491
Deschauer M, Hertel K, Zierz S (2003) Two novel mutations in the myophosphorylase gene in a patient with McArdle disease. Muscle Nerve 27:105–107
DiMauro S, Andreu AL, Bruno C, Hadjigeorgiou GM. (2002) Myophsophorylase deficiency (glycogenosis type V; McArdle disease). Curr Mol Med 2:189–196
Hudson JW, Golding GB, Crerar MM (1993) Evolution of allosteric control in glycogen phosphorylase. J Mol Biol 234:700–721
Isackson PJ, Tarnopolsky M, Vladutiu GD (2005) A novel mutation in the PYGM gene in a family with pseudodominant transmission of McARdle disease. Mol Genet Metab 85:239–242
Kubisch C, Wicklein EM, Jentsch TJ (1998) Molecular diagnosis of McArdle disease: revised genomic structure of the myophosphorylase gene and identification of a novel mutation. Hum Mutat 12:27–32
Martin MA, Rubio JC, Buchbinder J, Fernandez-Hojas R, del Hoyo P, Teijeira S, Gamez J, Navarro C, Fernandez JM, Cabello A, Campos Y, Cervera C, Culebras JM, Andreu AL, Fletterick R, Arenas J (2001) Molecular heterogeneity of myophosphorylase deficiency (McArdle’s disease): a genotype-phenotype correlation study. Ann Neurol 50:574–581
Martin MA, Rubio JC, Wevers RA, van Engelen BGM, Steenbergen GCH, van Diggelen OP, De Visser M, De Die-Smulders C, Blazquez A, Andreu AL, Arenas J (2003) Molecular analysis of myophosphorylase deficiency in Dutch patients with McArdle’s disease. Ann Hum Genet 68:17–22
Martinuzzi A, Tsujino S, Vergani L, Schievano G, Cadaldini M, Bartoloni L, Fanin M, Siciliano G, Shanske S, DiMauro S, Angelici C (1996) Molecular characterization of myophosphorylase deficiency in a group of patients from Northern Italy. J Neurol Sci 137:14–19
Quintans B, Sanchez-Andrade A, Teijeira S, Fernandez-Hojas R, Rivas E, Lopez MJ, Navarro C (2004) A new rare mutation (691del.CC/ins.AAA) in exon 17 of the PYGM gene causing McArdle disease. Arch Neurol 61:1108–1110
Sprang S, Fletterick RJ (1979) The structure of glycogen phosphorylase alpha at 2.5 A resolution. J Mol Biol 131:523–551
Sugie H, Sugie Y, Ito M, Fukada T, Nonaka I, Igarashi Y (1995) Genetic analysis of Japanese patients with myophosphorylase deficiency (McArdle’s disease): single-codon deletion in exon 17 is the predominant mutation. Clin Chim Acta 236:81–86
Tsujino S, Shanske S, DiMauro S (1993) Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle disease). N Engl J Med 329:241–245
Tsujino S, Shanske S, Martinuzzi A, Heiman-Patterson T, DiMauro S (1995) Two novel missense mutations (E654K, L396P) in Caucasian patients with myo-phosphorylase deficiency (McArdle’s disease). Hum Mutat 6:276–277
Vorgerd M, Kubisch C, Burwinkel B, Reichmann H, Mortier W, Tettenborn B, Pongratz D, Lindemuth R, Tegenthoff M, Malin J-P, Kilimann MW (1998) Mutation analysis in myophosphorylase deficiency (McArdle’s disease). Ann Neurol 43:326–331
Wolfe GI, Baker NS, Haller RG, Burns DK, Barohn RJ (2000) McArdle’s disease presenting with asymmetric, late-onset arm weakness. Muscle Nerve 23:641–645
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deschauer, M., Morgenroth, A., Joshi, P.R. et al. Analysis of spectrum and frequencies of mutations in McArdle disease. J Neurol 254, 797–802 (2007). https://doi.org/10.1007/s00415-006-0447-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-006-0447-x